News
First Needle-Free Epinephrine for Anaphylaxis Enters Real-World Clinical Use, Transforming Emergency Treatment for 32 Million Americans with Food Allergies
Neffy (epinephrine nasal spray), approved by the FDA in August 2024, is now in real-world clinical use as the first needle-free treatment for anaphylaxis. With summer outdoor activities creating an elevated allergy risk, here is why this device-free option is transforming emergency care for millions.
→
First-in-Class Drug Targeting Treatment-Resistant High Blood Pressure Wins FDA Approval — and Works Like No Existing Drug
FDA approved baxdrostat (Baxfendy) on May 18, 2026 as the first-ever oral aldosterone synthase inhibitor for uncontrolled and resistant hypertension. BaxHTN Phase 3 (NEJM 2025): 8.7–9.8 mmHg additional systolic blood pressure reduction added to background therapy. Here is the full story.
→
CRISPR Gene Editing Achieves a Functional Cure for Sickle Cell Disease in 96 Percent of Patients — RUBY Trial Results in the New England Journal of Medicine Are Historic
The RUBY Trial (NEJM, April 2026): CRISPR-Cas12a gene editing therapy reni-cel (renizgamglogene autogedtemcel) achieved a functional cure in 27 of 28 (96%) severe sickle cell disease patients, with no painful crises for up to two years after treatment. Led by Dr. Rabi Hanna at Cleveland Clinic.
→
MedstoreOnline
